CHICAGO--(Analyte Health, Inc., a privately held online medical services company offering specialty care, counseling and convenience not available in traditional primary care settings, announced today a new campaign to educate the public on high rates of hepatitis C among baby boomers. As part of that campaign, Analyte is offering reduced pricing to encourage more at-risk individuals to get tested through its two online clinics: Sexualhealth.com and STDTestExpress.com.)--
“Analyte’s new campaign is a direct response to the CDC’s initiative to improve screening for hepatitis C in the baby boomer population. Our goal is to get more people tested and improve lives”
Hepatitis C is an infectious disease that primarily affects the liver. Individuals infected with hepatitis C often do not have symptoms, but chronic infection can lead to scarring of the liver and ultimately to cirrhosis. In some cases cirrhosis can lead to liver failure, liver cancer or other life-threatening diseases. Data from the Centers for Disease Control (CDC) shows that people born between 1945 and 1965 are five times more likely to have the infection as people born earlier or later.
Analyte’s hepatitis C testing campaign, starting first on Facebook, uses infographics to illustrate the sobering statistics, along with testing discounts intended to reach more individuals in the at-risk population. The campaign launches with a tab hosted on the company’s Facebook page and 16 Facebook ads reaching 10 segments of the baby boomer population.
“Analyte’s new campaign is a direct response to the CDC’s initiative to improve screening for hepatitis C in the baby boomer population. Our goal is to get more people tested and improve lives,” said Lisa Oldson, M.D., the medical director at Analyte Health.
The CDC reports that more than 15,000 Americans, the majority of which are baby boomers, die each year from hepatitis C and related illnesses, and estimates that testing and early treatment of hepatitis C could save more than 120,000 lives.
Anthony Priore, Analyte Health Chief Marketing Officer, noted that “with more than 4,000 diagnostic labs in our network and doctors licensed in all 50 states, we can offer easy, quick and convenient testing. Social media is our lead marketing channel because of its flexibility and broad reach, and we know that this particular population is very active there.”
About Analyte Health, Inc.
Analyte Health is an innovative healthcare company based in Chicago, IL, that uses technology to help people gain greater access to expert medical care and information. Analyte Health delivers specialty care, counseling and convenience not available in a traditional primary care setting. Analyte Health offers individuals access via the web, mobile devices and telephone to a dedicated national team of doctors, nurses and health experts as well as more than 4,000 partner testing centers. Through more than 80,000 patient encounters to date, patients have trusted Analyte Health to deliver discreet and convenient STD testing and care. More information about the company is available at www.AnalyteHealth.com or on Facebook at https://www.facebook.com/SexHealthDotCom, Twitter at https://twitter.com/sexualhealth.
Analyte Health, Inc. is a privately held company. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits to consumers from using Analyte Health's services. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of risks and uncertainties, including, among other things, the potential impact of regulatory and third party payer developments in the field of telehealth and STD testing, general business and economic conditions, changes in arrangements with vendors or suppliers, and costs or delays in obtaining or maintaining regulatory approvals and licenses. Any forward-looking statements in this release are based on limited information currently available to Analyte Health, which is subject to change, and Analyte Health will not necessarily update the information.